<DOC>
	<DOC>NCT03062254</DOC>
	<brief_summary>Broadly, the objective of this study is to evaluate the fractional decline of intensity of tracer uptake measured by SUVmax on 68Ga-PSMA PET/CT in bone metastases from prostate cancer following treatment with radium-223 as a surrogate marker for tumor cell killing.</brief_summary>
	<brief_title>Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT Following Radium-223 Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Inclusion Criteria Resident of Canada Male sex Age 18 years or older Progressive (symptoms, conventional imaging, PSA, bone scan, FCH PET/CT or other) castrationresistant prostate cancer in the judgment of the treating physician without change in systemic antineoplastic therapy since documented progression Six or greater bone metastases robustlyavid on recent (4 weeks) MDP or NaF scintigraphy Recently failed (within 3 months) or failing novel androgen receptor pathway inhibitors (abiraterone + prednisone or enzalutamide) with intention of continuing the drug for at least 7 months OR minimum 14 day washout period from either agent prior to study enrollment No known visceral metastases or adenopathy greater than 3 cm short axis on conventional imaging Not received docetaxel for castrationresistant disease ECOG performance status 0 2, inclusive Life expectancy of greater than 6 months Serum testosterone less than or equal to 50 ng/dl Hemoglobin greater than or equal to 100 g/L with no blood transfusions or EPO in preceding 3 weeks Neutrophils greater than or equal to 1.5 x109/L Platelets greater than or equal to 100 x109/L No prior hemibody radiotherapy No impending or established spinal cord compression No unmanageable fecal incontinence Patient has good IV access Able to understand and provide written informed consent Exclusion Criteria Planned change in systemic antineoplastic therapy during the approximately 7 month trial Unable to tolerate the physical/logistical requirements of a PET/CT scan including lying supine for up to 30 minutes with the arms above the head and tolerating intravenous cannulation for injection of the study drug. Medically unstable patients (e.g. acute cardiac or respiratory distress or hypotensive, etc.) Patients who exceed the safe weight limit of the PET/CT bed (approximately 400 lbs.) or who cannot fit through the PET/CT bore (70 cm diameter) Patients who are claustrophobic</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PSMA</keyword>
</DOC>